EVAX Earnings

EVAX reported its earnings on 2026-05-07, showcasing a revenue of against an estimate of 15.83M, resulting in a 0% surprise. The EPS was -0.44, surpassing the expected 0 by 0%. The stock experienced a -7.71% price change on the earnings day and a -5.44% change over the next five days, reflecting market reactions to the results.

Following EVAX's earnings announcement on 2026-05-07, the stock price moved by -7.71% on the day of the release. Over the subsequent five days, it saw a -5.44% change. Historically, EVAX's stock price tends to shift by an average of -2.18% in the 10 days leading up to earnings and -1.21% in the 10 days following, providing insight into potential market.

For , analysts estimate EVAX's annual revenue to reach , while the EPS is projected at -0.25. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EVAX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EVAX's stock price typically moves by -2.18% in the 10 days before its earnings and -1.21% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.25 and revenue of .

The earnings call summary and Q&A reveal mixed signals. While the company has promising programs and a solid cash runway until 2027, the lack of concrete partnership updates and unproven scalability of the AI-Immunology platform pose risks. The financial performance is stable, but not exceptional, with a net loss in line with expectations. The operational changes and strategic focuses are promising but yet to show results. Given these factors, the stock is likely to remain stable over the next two weeks, resulting in a neutral rating.